In a major breakthrough in the filed of Biotech & Pharmaceutical Contract Research Services, Helix Genomics Pvt Ltd (Helix), a Bio-Computational Software Development & Contract Research Services company has signed a MOU with Cronos Therapeutics Ltd (CTL) of United Kingdom.

Dr Rajani Kanth Vangala, director & CSO told Pharmabiz, "We will be providing the critical Bio-Computational research services and undertake development of a specific Bio-analytical tool for designing target specific binding modules. Helix will custom build and develop the specific software modules for the designing of compounds for CTL."

CTL is a biopharmaceutical company established to develop a novel and groundbreaking class of therapeutics based on the unique and proprietary GeneICE platform. The company has developed a rapid and cost effective development program to bring this novel class of drugs to the marketplace. First lead compounds have been selected for GeneICE drug development.

Dr Vangala, who also heads Helix's UK operations added, GeneICE therapeutics can be designed to treat a wide range of diseases. The company will focus its own development projects in oncology, a field in which the company has core competence, and will seek licensing or collaborative opportunities in other therapeutic areas.

Helix has built a multi-skilled and multi-disciplinary R&D Center that offers cutting edge Contract Research Services for its clients.